Individualising care for patients with chronic hepatitis C: predicting side effects and treatment response using genomic and proteomic approaches.

慢性丙型肝炎患者的个体化护理：使用基因组和蛋白质组学方法预测副作用和治疗反应。

• 批准号: nhmrc : 1017139
• 负责人: Dr Paul Clark
• 金额: $ 3.71万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/individualising-care-patients-proteomic-approaches/109830
• 关键词: Individualising; care; patients; chronic; hepatitis

Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially improving the safety and efficacy of therapy.

接受丙型肝炎治疗的患者必须忍受以不可预测的治疗副作用和治愈可能性的不确定性为特征的治疗。该项目将研究治疗相关副作用的遗传预测因子和预测治疗反应的蛋白质标记物。更好地定义治疗的风险和获益，可能有助于患者和临床医生做出更明智的治疗决定，从而实现个体化治疗，并可能提高治疗的安全性和有效性。